The diagnostic value of C-reactive protein, interleukin-8, and monocyte chemotactic protein in risk stratification of febrile neutropenic children with hematologic malignancies

Journal of Pediatric Hematology/Oncology

Volumn 29, Issue 3, 2007, Pages 131-136

  El Maghraby, Shereen Mohamed ^a,b   Moneer, Manar Mohamed ^a   Ismail, Manar Mohamed ^a   Shalaby, Lobna M ^a   El Mahallawy, Hadir Ahmed ^a  

^a NATIONAL CANCER INSTITUTE   (Egypt)

^b NONE   (Egypt)

Author keywords

C reactive protein (CRP); Febrile neutropenia; Hematologic malignancies; Interleukin 8 (IL 8); Monocyte chemotactic protein 1 (MCP 1)

Indexed keywords

ANTINEOPLASTIC AGENT; C REACTIVE PROTEIN; INTERLEUKIN 8; MONOCYTE CHEMOTACTIC PROTEIN;

ACUTE LYMPHOBLASTIC LEUKEMIA; ACUTE NONLYMPHOCYTIC LEUKEMIA; ADOLESCENT; ADULT; ARTICLE; BACTEREMIA; BLOOD CULTURE; CHEMOTHERAPY; CHILD; COMPARATIVE STUDY; CONTROLLED STUDY; DIAGNOSTIC VALUE; FEBRILE NEUTROPENIA; FEMALE; FEVER; HEMATOLOGIC MALIGNANCY; HUMAN; INFECTION; MAJOR CLINICAL STUDY; MALE; NEUTROPENIA; NONHODGKIN LYMPHOMA; PREDICTION; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RISK ASSESSMENT; SENSITIVITY AND SPECIFICITY; SEPSIS;

ADOLESCENT; ANTI-BACTERIAL AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BACTEREMIA; C-REACTIVE PROTEIN; CHEMOKINE CCL2; CHILD; CHILD, PRESCHOOL; FEMALE; FEVER; HEMATOLOGIC NEOPLASMS; HUMANS; INFANT; INTERLEUKIN-8; LEUKEMIA; MALE; NEUTROPENIA; PREDICTIVE VALUE OF TESTS; PROGNOSIS; PROSPECTIVE STUDIES; REFERENCE VALUES; RISK FACTORS; TREATMENT OUTCOME;

EID: 34247623669     PISSN: 10774114     EISSN: 15363678     Source Type: Journal    
DOI: 10.1097/MPH.0b013e3180308770     Document Type: Article

References (19)

1. Cordonnier C. Management of infectious complications in hematological patients. In: Degos L, Linch D, Loweberg B, eds. Textbook of Malignant Hematology. London and Newyork: Taylor and Francis Group; 2005:811-826.
2. Alexander S, Walsh T, Freifeld A, et al. Infectious complications in pediatric cancer patients. In: Pizzo P, Poplack D, eds. Principles and Practice of Pediatric Oncology. Philadelphia: Lippincott Williams and Wilkins; 2002:1239-1283.
3. Alexander SW, Wade KC, Hibberd PL, et al. Evaluation of risk prediction criteria for episodes of febrile neutropenia in children with cancer. J Pediatr Hematol Oncol. 2002;24:38-42.
4. Kock A, Pizzo PA. Empirical oral antibiotic therapy for low risk febrile cancer patients with neutropenia. Cancer Invest. 2002;20:420-433.
5. Klastersky J. Management of fever in neutropenic patients with different risks of complications. Clin Infect Dis. 2004;39:32-37.
6. Picazo JJ. Management of the febrile neutropenic patient. Int J Antimicrob Agents. 2005;26:120-122.
7. Bayer L, Schontube M, Dorffel W. C reactive protein, IL6 and procalcitonin as infection parameters in children with oncologic diseases. Klin Padiatr. 2000;212:326-331.
8. Schuger NW, Rom WN. Early responses to infection: chemokines as mediators of inflammation. Curr Opin Immunol. 1997;9:504-508.
9. Innes H, Billingham L, Gaunt C, et al. Management of febrile neutropenia in the United Kingdom: time for a national trial? Br J Cancer. 2005;93:1324-1328.
10. Klastersky J, Paesmans M, Rubenstein EB, et al. The Multinational Association for Supportive Care in Cancer risk index: a multinational scoring system for identifying low-risk febrile neutropenic cancer patients. J Clin Oncol. 2000;18:3038-3051.
11. Santolaya ME, Alvarez AM, Becker A, et al. Prospective, multicenter evaluation of risk factors associated with invasive bacterial infection in children with cancer, neutropenia, and fever. J Clin Oncol. 2001;19:3415-3421.
12. Santolaya ME, Alvarez AM, Aviles CL, et al. Prospective evaluation of a model of prediction of invasive bacterial infection risk among children with cancer, fever, and neutropenia. Clin Infect Dis. 2002;35:678-683.
13. Cordonnier C. The feasibility of early discharge with oral antimicrobial therapy in risk neutropenia following chemotherapy for hematologic malignancies. Haematologica. 2006;91:150.
14. Bossink AW, Paemen L, Jansen PM, et al. Plasma levels of the chemokines monocyte chemotactic proteins-1 and 2 are elevated in human sepsis. Blood. 1995;86:3841.
15. Kern W, Heiss M, Steinbach G. Prediction of gram negative bacteremia in patients with cancer and febrile neutropenia by means of IL-8 levels in serum: targeting empirical monotherapy versus combination therapy. Clin Infect Dis. 2001;32:832-835.
16. Engel A, Stefanie K, Kern P, et al. Interleukin-8 serum levels at fever onset in patients with neutropenia predict early medical complications. Infection. 2005;33:380-382.
17. Celkan T, Ozkan A, Apak H, et al. Bacteremia in childhood cancer. J Trop Pediatr. 2002;48:373-376.
18. Fischer JE, Benn A, Harbarth S, et al. Diagnostic accuracy of G-CSF, IL-8, and IL-1ra in critically ill children with suspected infection. Intensive Care Med. 2002;28:1324-1331.
19. de Bont ES, Vellenga E, Swaanenburg JC, et al. Plasma IL-8, and IL-6 levels can be used to define a group with low risk of septicaemia among cancer patients with fever and neutropenia. Br J Haematol. 2001;114:489-491.